Immunogenicity of a DNA and recombinant protein vaccine combining LipL32 and Loa22 for leptospirosis using chitosan as a delivery system

Journal of Microbiology and Biotechnology

Volumn 25, Issue 4, 2015, Pages 526-536

  Umthong, Supawadee ^a   Buaklin, Arun ^a   Jacquet, Alain ^a   Sangjun, Noppadol ^b   Kerdkaew, Ruthairat ^a   Patarakul, Kanitha ^a   Palaga, Tanapat ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

Chitosan; DNA vaccine; Immunogenicity; Leptospirosis

Indexed keywords

CHITOSAN; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LEPTOSPIROSIS VACCINE; LIPL32 VACCINE; LOA22 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CYTOKINE; IMMUNOGLOBULIN G; LIPL32 PROTEIN, LEPTOSPIRA; LIPOPROTEIN; NANOPARTICLE; OUTER MEMBRANE PROTEIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL STRAIN; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; LEPTOSPIROSIS; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OPEN READING FRAME; PARTICLE SIZE; PLASMID; PROTEIN PURIFICATION; SCANNING ELECTRON MICROSCOPY; SPLEEN CELL; TH1 CELL; TH2 CELL; ANIMAL; BLOOD; CELL LINE; CHEMISTRY; DISEASE MODEL; IMMUNIZATION; IMMUNOLOGY; LEPTOSPIRA; METABOLISM; T LYMPHOCYTE; VACCINATION;

LEPTOSPIRA; MUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; CELL LINE; CHITOSAN; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; LEPTOSPIRA; LEPTOSPIROSIS; LIPOPROTEINS; MICE; NANOPARTICLES; RECOMBINANT PROTEINS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC;

EID: 84928168910     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: 10.4014/jmb.1408.08007     Document Type: Article

References (40)

1. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, Dolganov G, et al. 2011. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17: 189-194.
2. Adler B, de la Pena Moctezuma A. 2010. Leptospira and leptospirosis. Vet. Microbiol. 140: 287-296.
3. Alpar HO, Bramwell VW. 2002. Current status of DNA vaccines and their route of administration. Crit. Rev. Ther. Drug Carrier Syst. 19: 307-383.
4. Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, et al. 2003. Leptospirosis: a zoonotic disease of global importance. Lancet Infect. Dis. 3: 757-771.
5. Bolin CA, Cassells JA, Zuerner RL, Trueba G. 1991. Effect of vaccination with a monovalent Leptospira interrogans serovar Hardjo type Hardjo-Bovis vaccine on type Hardjo-Bovis infection of cattle. Am. J. Vet. Res. 52: 1639-1643.
6. Branger C, Chatrenet B, Gauvrit A, Aviat F, Aubert A, Bach JM, Andre-Fontaine G. 2005. Protection against Leptospira interrogans sensu lato challenge by DNA immunization with the gene encoding hemolysin-associated protein 1. Infect. Immun. 73: 4062-4069.
7. Branger C, Sonrier C, Chatrenet B, Klonjkowski B, Ruvoen-Clouet N, Aubert A, et al. 2001. Identification of the hemolysis-associated protein 1 as a cross-protective immunogen of Leptospira interrogans by adenovirus-mediated vaccination. Infect. Immun. 69: 6831-6838.
8. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503.
9. Cui Z, Mumper RJ. 2001. Chitosan-based nanoparticles for topical genetic immunization. J. Control. Release 75: 409-419.
10. Cullen PA, Cordwell SJ, Bulach DM, Haake DA, Adler B. 2002. Global analysis of outer membrane proteins from Leptospira interrogans serovar Lai. Infect. Immun. 70: 2311-2318.
11. Feng CY, Li QT, Zhang XY, Dong K, Hu BY, Guo XK. 2009. Immune strategies using single-component LipL32 and multi-component recombinant LipL32-41-OmpL1 vaccines against Leptospira. Braz. J. Med. Biol. Res. 42: 796-803.
12. Guerreiro H, Croda J, Flannery B, Mazel M, Matsunaga J, Galvao Reis M, et al. 2001. Leptospiral proteins recognized during the humoral immune response to leptospirosis in humans. Infect. Immun. 69: 4958-4968.
13. Haake DA, Chao G, Zuerner RL, Barnett J K, Barnett D, Mazel M, et al. 2000. The leptospiral major outer membrane protein LipL32 is a lipoprotein expressed during mammalian infection. Infect. Immun. 68: 2276-2285.
14. Haake DA, Mazel MK, McCoy AM, Milward F, Chao G, Matsunaga J, Wagar EA. 1999. Leptospiral outer membrane proteins OmpL1 and LipL41 exhibit synergistic immunoprotection. Infect. Immun. 67: 6572-6582.
15. Haake DA, Suchard MA, Kelley MM, Dundoo M, Alt D P, Zuerner RL. 2004. Molecular evolution and mosaicism of leptospiral outer membrane proteins involves horizontal DNA transfer. J. Bacteriol. 186: 2818-2828.
16. Hall J, Hazlewood GP, Surani MA, Hirst BH, Gilbert HJ. 1990. Eukaryotic and prokaryotic signal peptides direct secretion of a bacterial endoglucanase by mammalian cells. J. Biol. Chem. 265: 19996-19999.
17. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al. 2008. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205: 63-77.
18. Herrmann JL, Bakoss P, Korver H, Bulu AA, Bellenger E, Terpstra WJ, et al. 1994. A new serovar in the Grippotyphosa serogroup comprising leptospiral isolates from different regions. Int. J. Syst. Bacteriol. 44: 362-364.
19. Herrmann JL, Baril C, Bellenger E, Perolat P, Baranton G, Saint Girons I. 1991. Genome conservation in isolates of Leptospira interrogans. J. Bacteriol. 173: 7582-7588.
20. Jost BH, Adler B, Vinh T, Faine S. 1986. A monoclonal antibody reacting with a determinant on leptospiral lipopolysaccharide protects guinea pigs against leptospirosis. J. Med. Microbiol. 22: 269-275.
21. Koizumi N, Watanabe H. 2003. M olecular c loning a nd characterization of a novel leptospiral lipoprotein with OmpA domain. FEMS Microbiol. Lett. 226: 215-219.
22. Lu S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21: 346-351.
23. Magalhaes I, Sizemore DR, Ahmed RK, Mueller S, Wehlin L, Scanga C, et al. 2008. rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 3: e3790.
24. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. 2001. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release 70: 399-421.
25. McBride AJ, Athanazio DA, Reis MG, Ko AI. 2005. Leptospirosis. Curr. Opin. Infect. Dis. 18: 376-386.
26. Monahan AM, Callanan JJ, Nally JE. 2008. Proteomic analysis of Leptospira interrogans shed in urine of chronically infected hosts. Infect. Immun. 76: 4952-4958.
27. Murray GL. 2013. The lipoprotein LipL32, an enigma of leptospiral biology. Vet. Microbiol. 162: 305-314.
28. Naiman BM, Alt D, Bolin CA, Zuerner R, Baldwin CL. 2001. Protective killed Leptospira borgpetersenii vaccine induces potent Th1 immunity comprising responses by CD4 and gammadelta T lymphocytes. Infect. Immun. 69: 7550-7558.
29. Nally JE, Whitelegge JP, Bassilian S, Blanco DR, Lovett MA. 2007. Characterization of the outer membrane proteome of Leptospira interrogans expressed during acute lethal infection. Infect. Immun. 75: 766-773.
30. Picardeau M, Bulach DM, Bouchier C, Zuerner RL, Zidane N, Wilson PJ, et al. 2008. Genome sequence of the saprophyte Leptospira biflexa provides insights into the evolution of Leptospira and the pathogenesis of leptospirosis. PLoS One 3: e1607.
31. Pinne M, Haake DA. 2013. LipL32 is a subsurface lipoprotein of Leptospira interrogans: presentation of new data and reevaluation of previous studies. PLoS One 8: e51025.
32. Ristow P, Bourhy P, da Cruz McBride FW, Figueira CP, Huerre M, Ave P, et al. 2007. The OmpA-like protein Loa22 is essential for leptospiral virulence. PLoS Pathog. 3: e97.
33. Seixas FK, da Silva EF, Hartwig DD, Cerqueira GM, Amaral M, Fagundes MQ, et al. 2007. Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 26: 88-95.
34. Srikram A, Zhang K, Bartpho T, Lo M, Hoke DE, Sermswan RW, et al. 2011. Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant. J. Infect. Dis. 203: 870-879.
35. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52: 139-144.
36. Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350: 34-47.
37. Wang S, Parker C, Taaffe J, Solorzano A, Garcia-Sastre A, Lu S. 2008. Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 26: 3626-3633.
38. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468.
39. Yan W, Faisal SM, McDonough S P, Chang C F, Pan M J, Akey B, Chang YF. 2010. Identification and characterization of OmpA-like proteins as novel vaccine candidates for leptospirosis. Vaccine 28: 2277-2283.
40. Zuerner R L, Alt DP, Palmer MV, Thacker T C, Olsen S C. 2011. A Leptospira borgpetersenii serovar Hardjo vaccine induces a Th1 response, activates NK cells, and reduces renal colonization. Clin. Vaccine Immunol. 18: 684-691.